Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Hu, Chen-Yu, Xu, Xiang-Ming, Hong, Bo, Wu, Zhi-Gang, Qian, Yun, Weng, Tian-Hao, Liu, Yi-Zhi, Tang, Tao-Ming, Wang, Ming-Hai, Yao, Hang-Ping
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906148/
https://ncbi.nlm.nih.gov/pubmed/31867280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01377
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados